Mkts

REGENXBIO Inc.

NASDAQ: RGNX
$8.07+0.45 (+5.91%)
As of Nov 9, 4:00 PM ET

Key statistics

Day range
7.478.23
52-week range
5.4616.19
Today
Open7.77
Previous close8.07
Volume1.04M
Valuation
Market cap527.00M
P/E ratio—
EPS (TTM)-3.79
Income & risk
Dividend / yield—
Beta1.18
Avg volume1.54M
Discussion

RGNX News

Stories mentioning RGNX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue6,39330,33729,73321,35989,01221,21424,19722,295
Cost of Goods Sold6,31812,38710,579
Gross Profit14,89611,81011,716
Operating Expenses
Research & Development57,33959,61156,10159,50053,08750,38054,42948,869
Sales General & Admin
Total Operating Expenses
Operating Income (Loss)(83,362)(57,636)(52,411)(63,278)12,127(51,368)(62,078)(56,037)
Interest Income2,0002,7003,6003,4002,5002,8003,3003,500
Interest Expense449.00
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(90,051)(67,149)(61,941)(70,871)6,083(51,186)(59,597)(52,989)
Earnings Per Share (Basic)(1.72)(1.30)(1.20)(1.38)0.12(1.03)(1.17)(1.05)
Earnings Per Share (Diluted)(1.72)(1.30)(1.20)(1.38)0.12(1.03)(1.17)(1.05)
Weighted Average Shares Outstanding (Basic)52,42851,57351,68951,48351,36249,50950,80050,601
Weighted Average Shares Outstanding (Diluted)52,42851,57351,68951,48351,43449,50950,80050,601

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About RGNX

REGENXBIO Inc. (NASDAQ: RGNX) is a stock listed on the Nasdaq Stock Market under the ticker symbol RGNX. It last traded at $8.07 (Nov 9, 2026, 4:00 PM ET), up 5.9% on the day. That gives REGENXBIO a market capitalisation of $527.0M.

Over the past 52 weeks RGNX has traded between $5.46 and $16.19.

Revenue for the quarter ended Mar 31, 2026 was $6.4M; a net loss of $90.1M. Revenue was down 92.8% from $89.0M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$6.4M-$90.1M-1408.6%
Dec 31, 2025$30.3M-$67.1M-221.3%
Sep 30, 2025$29.7M-$61.9M-208.3%
Jun 30, 2025$21.4M-$70.9M-331.8%

From REGENXBIO’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…